A GLP-1 Drug Cut Heavy Drinking in a Trial for Alcohol Use Disorder

The GLP-1 drug class keeps revealing surprises. A Phase 2 trial suggests Altimmune’s pemvidutide can reduce heavy drinking in people with alcohol use disorder — adding to interest in whether these medicines blunt cravings beyond food.

What the trial showed

The placebo-controlled study enrolled 100 participants with alcohol use disorder and obesity. At 24 weeks, the pemvidutide group cut heavy-drinking days by an average of 4.2 days per week, versus 2.75 for placebo.

42.2% of those on the drug reached zero heavy-drinking days, compared with under 21% on placebo.

The abstinence-from-heavy-drinking figure is the more meaningful of the two. A reduction in average days is a continuous measure whose clinical significance is arguable; the proportion reaching zero is a categorical outcome that corresponds to what treatment aims at.

The placebo response is also worth noting. Nearly 21% reaching zero without active drug reflects that people entering an alcohol trial are motivated to change and receive structured contact and monitoring — which is itself an intervention.

How the drug works

Pemvidutide is a once-weekly injectable activating both the GLP-1 and glucagon receptors — the GLP-1 arm curbing appetite, the glucagon arm targeting liver fat.

The dual mechanism was designed for metabolic liver disease rather than for addiction. Glucagon receptor activation increases energy expenditure and promotes breakdown of fat stored in the liver, which is the target in that condition.

Its effect on drinking fits a growing pattern: GLP-1-class drugs appear to influence the brain’s reward circuitry, not just hunger.

Why a food drug would affect alcohol

The connection is less surprising than it first appears, because the brain does not maintain separate systems for different rewards.

GLP-1 receptors are expressed in brain regions central to reward processing, including areas where addictive substances act. Reducing signalling through those circuits would be expected to reduce the reinforcing value of rewards generally — food among them, but not only food.

Reports from patients taking these drugs for weight loss have described exactly that: reduced interest in alcohol, and in some accounts other compulsive behaviours, without intending it.

Animal studies preceded those reports, showing reduced alcohol consumption in rodents given GLP-1 agonists, which makes the human observations more credible than anecdote alone would.

Why the population matters

Participants had alcohol use disorder and obesity, which is a real limitation on interpretation.

The overlap is clinically genuine — alcohol contributes substantial calories and the two conditions co-occur — so the population is not artificial. But it means the result does not establish that the drug helps people with alcohol use disorder who are not obese.

It also leaves open whether some of the effect operates through weight loss or dietary change rather than directly on reward circuitry.

Why any new option matters

Effective medications for alcohol use disorder are scarce.

Three drugs are approved in most jurisdictions, with modest average effects, and they are prescribed to a small fraction of people who might benefit. One works by making alcohol consumption unpleasant, which requires the patient to take it consistently while wanting to drink; the others reduce craving with variable success.

A drug already manufactured at scale, prescribed by ordinary clinicians and carrying a familiar safety profile would sidestep much of what keeps addiction pharmacotherapy underused.

The caveats

The data show “strong and consistent efficacy across important measures,” said Altimmune chief medical officer Christophe Arbet-Engels.

This is a mid-stage trial in 100 people, and it is not entirely clean: one serious case of low blood sodium in the drug group was deemed possibly related. Hyponatraemia is potentially serious and warrants attention in a larger study, particularly in a population where alcohol itself disturbs sodium balance.

Why the liver angle is not incidental

Pemvidutide was developed for metabolic liver disease, and that origin has a specific relevance to alcohol use disorder beyond a convenient repurposing.

Alcohol damages the liver directly, progressing through fat accumulation to inflammation and ultimately to cirrhosis. Metabolic liver disease driven by obesity follows a strikingly similar histological path, and the two frequently coexist — a patient who drinks heavily and carries excess weight has both processes operating on the same organ.

That co-occurrence accelerates progression. Studies indicate that obesity and heavy drinking together produce more liver damage than either alone, beyond simple addition.

A drug that reduces both drinking and liver fat therefore acts on two contributors to the same endpoint. For a patient with both conditions, that is a more coherent proposition than treating either separately — and it may explain why the trial enrolled the population it did, since the drug’s existing indication and the addiction finding converge on exactly those patients.

Altimmune plans to discuss a path forward with the FDA. This is early-stage research, not an approved treatment or medical advice.